UY39798A - Anticuerpos anti-ccr8 y usos de los mismos - Google Patents

Anticuerpos anti-ccr8 y usos de los mismos

Info

Publication number
UY39798A
UY39798A UY0001039798A UY39798A UY39798A UY 39798 A UY39798 A UY 39798A UY 0001039798 A UY0001039798 A UY 0001039798A UY 39798 A UY39798 A UY 39798A UY 39798 A UY39798 A UY 39798A
Authority
UY
Uruguay
Prior art keywords
ccr8 antibodies
ccr8
antibodies
antigen
binding fragments
Prior art date
Application number
UY0001039798A
Other languages
English (en)
Inventor
Agnieszka Kielczewska
L Bates Darren
William Pierce Nathan
Wentao Chen
Nolan-Stevaux Olivier
Lisa Winkel
Christoph Dahlhoff
Claudia Bluemel
Karl-Josef Honer Jonas
Tobias Raum
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh filed Critical Amgen Inc
Publication of UY39798A publication Critical patent/UY39798A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos, y métodos de fabricación y uso de dichos anticuerpos anti-CCR8 y fragmentos de unión a antígeno de los mismos.
UY0001039798A 2021-06-04 2022-06-02 Anticuerpos anti-ccr8 y usos de los mismos UY39798A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163197271P 2021-06-04 2021-06-04
US202163236551P 2021-08-24 2021-08-24

Publications (1)

Publication Number Publication Date
UY39798A true UY39798A (es) 2022-12-30

Family

ID=82358418

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039798A UY39798A (es) 2021-06-04 2022-06-02 Anticuerpos anti-ccr8 y usos de los mismos

Country Status (16)

Country Link
US (1) US20220403037A1 (es)
EP (1) EP4347655A1 (es)
JP (1) JP2024522360A (es)
KR (1) KR20240017912A (es)
AU (1) AU2022285741A1 (es)
BR (1) BR112023025433A2 (es)
CA (1) CA3222764A1 (es)
CL (1) CL2023003607A1 (es)
CO (1) CO2023018064A2 (es)
CR (1) CR20230581A (es)
IL (1) IL308808A (es)
MX (1) MX2023014458A (es)
PE (1) PE20240363A1 (es)
TW (1) TW202313684A (es)
UY (1) UY39798A (es)
WO (1) WO2022256563A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39798A (es) * 2021-06-04 2022-12-30 Amgen Inc Anticuerpos anti-ccr8 y usos de los mismos
US20240165227A1 (en) * 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024165469A1 (en) 2023-02-06 2024-08-15 Bayer Aktiengesellschaft Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
JP6475017B2 (ja) 2011-10-27 2019-02-27 ゲンマブ エー／エス ヘテロ二量体タンパク質の作出
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2018002226A (es) * 2015-08-28 2018-03-23 Amunix Operating Inc Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
JP6501171B2 (ja) 2017-03-29 2019-04-17 塩野義製薬株式会社 癌治療用医薬組成物
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
JP2023509323A (ja) * 2020-01-06 2023-03-08 ヴァクシネックス， インコーポレイテッド 抗ｃｃｒ８抗体及びその使用
TW202216771A (zh) * 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
AU2021329374A1 (en) 2020-08-20 2023-03-09 Amgen Inc. Antigen binding proteins with non-canonical disulfide in FAB region
EP4186926A4 (en) * 2020-08-28 2024-06-05 Harbour Biomed US, Inc. ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION
AU2021360782A1 (en) * 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2022287014A1 (en) * 2021-06-04 2023-12-07 Amgen Inc. T cell engager molecules and uses thereof
UY39798A (es) * 2021-06-04 2022-12-30 Amgen Inc Anticuerpos anti-ccr8 y usos de los mismos

Also Published As

Publication number Publication date
EP4347655A1 (en) 2024-04-10
CO2023018064A2 (es) 2024-01-15
WO2022256563A1 (en) 2022-12-08
JP2024522360A (ja) 2024-06-18
KR20240017912A (ko) 2024-02-08
BR112023025433A2 (pt) 2024-02-27
MX2023014458A (es) 2023-12-15
US20220403037A1 (en) 2022-12-22
CA3222764A1 (en) 2022-12-08
CR20230581A (es) 2024-02-13
IL308808A (en) 2024-01-01
CL2023003607A1 (es) 2024-06-07
PE20240363A1 (es) 2024-03-04
TW202313684A (zh) 2023-04-01
AU2022285741A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CO2021000419A2 (es) Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CL2020003391A1 (es) Proteína de unión al antígeno anti-steap1
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
CO2022014878A2 (es) Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos
BR112023024837A2 (pt) Anticorpos anti-ccr8
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
AR120883A1 (es) Anticuerpos anti-fgfr2b
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
CO2023010689A2 (es) Anticuerpos y usos de estos
CO2022010244A2 (es) Anticuerpos anti-e-selectina, composiciones y métodos de uso
AR120886A1 (es) Anticuerpos anti-fgfr2b
AR120884A1 (es) Anticuerpos anti-fgfr2b
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
PE20230765A1 (es) Anticuerpo anti-cd47 y usos del mismo
AR115987A1 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
AR117578A1 (es) Anticuerpos específicos para cd3 y sus usos